Detailed Information for C00573

Basic information about inhibitors

IPAD-DB ID C00573
Name Verbenalin
Category Natural compounds
2D Structure
3D Structure
Molecular Formula C 1 7 H 2 4 O 1 0
Molecular Weight 388.4g/mol
IUPAC Name methyl (1S, 4aS, 7S, 7aR)-7-methyl-5-oxo-1-[(2S, 3R, 4S, 5S, 6R)-3, 4, 5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a, 6, 7, 7a-tetrahydro-1H-cyclopenta[c]pyran-4-carboxylate
InChI InChI=1S/C17H24O10/c1-6-3-8(19)11-7(15(23)24-2)5-25-16(10(6)11)27-17-14(22)13(21)12(20)9(4-18)26-17/h5-6, 9-14, 16-18, 20-22H, 3-4H2, 1-2H3/t6-, 9+, 10+, 11-, 12+, 13-, 14+, 16-, 17-/m0/s1
InChIKey HLXRWTJXGMHOFN-XJSNKYLASA-N
Canonical SMILES CC1CC(=O)C2C1C(OC=C2C(=O)OC)OC3C(C(C(C(O3)CO)O)O)O
PubChem CID 73467
DrugBank Accession Number -
CAS Registry Number 548-37-8

Biological activity data

Ki -
EC50 -
IC50 -
Inhibition -
Toxicity The neuroprotective effect of verbenalin against Aβ-induced cytotoxicity in SH-SY5Y cells
ROS(reactive oxygen species) Verbenalin treatment attenuated Aβ-induced reactive oxygen species (ROS) generation in SH-SY5Y cells
Metal Chelating -
BBB(blood-brain barrier) -
Target Protein
Effects (1) Verbenalin treatment significantly ameliorated the Aβ-induced decline of ATP levels in SH-SY5Y cells, (2)Verbenalin treatment regulated the expressions of EGFR, VEGF, and NRG1 in Aβ-induced SH-SY5Y cells,
Research Models Human neuroblastoma SH-SY5Y cells
Main Source An iridoid glucoside found in medicinal herbs of Verbenaceae family
Ref. Link

Physicochemical properties

Molecular Weight(Computed by SwissADME) 388.37
Hac(Computed by SwissADME) 27
Volume(Computed by ADMETlab 2.0) 356.912
Density(Computed by ADMETlab 2.0) 1.087
nRing(Computed by ADMETlab 2.0) 3
MaxRing(Computed by ADMETlab 2.0) 9
nHet(Computed by ADMETlab 2.0) 10
fChar(Computed by ADMETlab 2.0) 0
nRig(Computed by ADMETlab 2.0) 18
Flexibility(Computed by ADMETlab 2.0) 0.278
Stero Centers(Computed by ADMETlab 2.0) 8
LogS(Computed by ADMETlab 2.0) -1.052
LogD(Computed by ADMETlab 2.0) 0.06

ADMET properties

logP(Computed by ADMETlab 2.0) -1.94
TPSA(Computed by SwissADME) 151.98 Ų
Hbond Acceptor(Computed by SwissADME) 10
Hbond Donor(Computed by SwissADME) 4
Rotatable Bonds(Computed by SwissADME) 5

Pharmacokinetics

GI Absorption(Computed by SwissADME) Low
BBB(blood-brain barrier) Permeant(Computed by SwissADME) No
P-gp Substrate(Computed by SwissADME) Yes
CYP1A2 Inhibitor(Computed by SwissADME) No
CYP2C19 Inhibitor(Computed by SwissADME) No
CYP2C9 Inhibitor(Computed by SwissADME) No
CYP2D6 Inhibitor(Computed by SwissADME) No
CYP3A4 Inhibitor(Computed by SwissADME) No
log Kp(Skin Permeation)(Computed by SwissADME) -9.73 cm/s

Druglikeness

Lipinski(Computed by SwissADME) Yes, 0 violation
Ghose(Computed by SwissADME) No, 1 violation: WLOGP<-0.4
Veber(Computed by SwissADME) No, 1 violation: TPSA>140
Egan(Computed by SwissADME) No, 1 violation: TPSA>131.6
Muegge(Computed by SwissADME) No, 1 violation: TPSA>150
Bioavailability Score(Computed by SwissADME) 0.11